Shionogi’s COVID-19 Jab Non-Inferior to Pfizer Shot in Japan Booster Trial

Shionogi President Isao Teshirogi at Press Conference on March 4 (Courtesy of Shionogi) Shionogi said on March 4 that its COVID-19 vaccine S-268019 demonstrated non-inferiority to Pfizer’s Comirnaty in a PII/III booster shot trial in Japan, achieving the primary immunogenicity...read more